All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ponesimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
immunomodulators, both stimulant/suppressive and stimulant	5446	854107-55-4

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: ponesimod ponvory ACT-128800

Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system Molecular weight: 460.97 Formula: C23H25ClN2O4S CLOGP: 4.81 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 82.36 ALOGS: -4.87 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 19, 2021	EMA	Janssen-Cilag International N.V.
March 18, 2021	FDA	JANSSEN PHARMACEUTICALS Inc

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA50	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D000081243	Sphingosine 1 Phosphate Receptor Modulators
FDA MoA	N0000181815	Sphingosine 1-Phosphate Receptor Modulators
FDA EPC	N0000181816	Sphingosine 1-phosphate Receptor Modulator

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Relapsing forms of multiple sclerosis	indication	24700007	DOID:2377
Unstable angina	contraindication	4557003
Myocardial infarction	contraindication	22298006	DOID:5844
Complete atrioventricular block	contraindication	27885002
Mobitz type II atrioventricular block	contraindication	28189009	DOID:11312
Sick sinus syndrome	contraindication	36083008	DOID:13884
Heart failure	contraindication	84114007	DOID:6000
Decompensated cardiac failure	contraindication	195111005
Cerebrovascular accident	contraindication	230690007
Transient ischemic attack	contraindication	266257000	DOID:224

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9000018	Nov. 16, 2024	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	8273779	Dec. 17, 2025	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	9062014	May 6, 2032	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
20MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
2MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
3MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
4MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
5MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
6MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
7MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
8MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
9MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	10220023	Dec. 10, 2035	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
20MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
2MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
3MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
4MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
5MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
6MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
7MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
8MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY
9MG	PONVORY	JANSSEN PHARMS	N213498	March 18, 2021	RX	TABLET	ORAL	March 18, 2026	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sphingosine 1-phosphate receptor 1	GPCR	P21453	S1PR1_HUMAN	AGONIST	EC50	8.13		SCIENTIFIC LITERATURE	DRUG LABEL
Sphingosine 1-phosphate receptor 5	GPCR	Q9H228	S1PR5_HUMAN	AGONIST	EC50	7.23		SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 4	GPCR	O95977	S1PR4_HUMAN	AGONIST	EC50	5.96		SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 3	GPCR	Q99500	S1PR3_HUMAN	AGONIST	EC50	6.94		SCIENTIFIC LITERATURE

External reference:

ID	Source
D11215	KEGG_DRUG
5G7AKV2MKP	UNII
C2934701	UMLSCUI
CHEMBL1096146	ChEMBL_ID
11363176	PUBCHEM_CID
DB12016	DRUGBANK_ID
CHEMBL1095833	ChEMBL_ID
9320	IUPHAR_LIGAND_ID
018671	NDDF
1179253008	SNOMEDCT_US
1179254002	SNOMEDCT_US
4040289	VANDF
2532300	RXNORM
344652	MMSL
39406	MMSL
d09723	MMSL
C550169	MESH_SUPPLEMENTAL_RECORD_UI
9150	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PONVORY	HUMAN PRESCRIPTION DRUG LABEL	1	50458-720	TABLET, FILM COATED	20 mg	ORAL	NDA	32 sections
PONVORY	HUMAN PRESCRIPTION DRUG LABEL	1	50458-720	TABLET, FILM COATED	20 mg	ORAL	NDA	32 sections